September 30, 2026
with Independent Auditor's Review Report
Rede D'Or São Luiz S.A. Interim financial information September 30, 2026
Contents
Independent auditor's review report on interim financial information 1
Interim financial information
Statements of financial position 3
Statements of profit or loss 5
Statements of comprehensive income 6
Statements of changes in equity 7
Statements of cash flows 8
Statements of value added 9
Notes to the interim financial information 10
Centro Empresarial PB 370
Praia de Botafogo, 370
8º ao 10º andar - Botafogo
22250-040 - Rio de Janeiro - RJ - Brazil Phone: +55 21 3263-7000
ey.com.br
Independent auditor's review report on interim financial informationTo the Shareholders, Board of Directors and Officers of
Rede D'Or São Luiz S.A.Rio de Janeiro - RJ, Brazil
IntroductionWe have reviewed the accompanying individual and consolidated interim financial information contained in the Quarterly Information Form (ITR) of Rede D'Or São Luiz S.A. (the "Company") for the quarter ended September 30, 2026, which comprises the statement of financial position as of September 30, 2026, and the related statements of profit or loss and of comprehensive income for the three and nine-month periods then ended, and of changes in equity and of cash flows for the nine-month period then ended, including the explanatory notes.
The executive board is responsible for the preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting, and with IAS 34 - Interim Financial Reporting (IFRS Accounting Standards), issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information Form (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.
Scope of reviewWe conducted our review in accordance with Brazilian and international standards on review engagements (NBC TR 2410 and ISRE 2410 Review of Interim Financial Information Performed by
the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion on the individual and consolidated interim financial informationBased on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with Accounting Pronouncement CPC 21 (R1) and IAS 34 applicable to the preparation of Quarterly Information Form (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).
1
A member firm of Ernst & Young Global Limited
Other matters - Statements of value addedThe abovementioned quarterly information includes the individual and consolidated statements of value added (SVA) for the nine-month period ended September 30, 2026, prepared under the responsibility of the Company's executive board and presented as supplementary information under IAS 34. These statements have been subject to the same review procedures performed together with quarterly information review, in order to conclude whether they have been reconciled to the interim financial information and accounting records, as applicable, and whether their form and content are in accordance the criteria defined in Accounting Pronouncement CPC 09 - Statement of Value Added.
Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not prepared, in all material respects, in accordance with the criteria set forth by this standard and consistently with the individual and consolidated interim financial information as a whole.
Rio de Janeiro, November 11, 2026. ERNST & YOUNG
Auditores Independentes S/S Ltda. CRC SP-015199/F
Wilson J.O. Moraes Accountant CRC RJ-107211/O
Assets Current assets
Cash and cash equivalents | 4 | 728,396 | 214,163 | 3,209,997 | 3,705,415 |
Securities | 4 | 8,766,492 | 8,410,483 | 39,447,148 | 36,855,083 |
Accounts receivable | 5 | 5,402,603 | 5,312,008 | 10,511,349 | 10,167,395 |
Inventories | 6 | 582,782 | 527,778 | 1,276,035 | 1,196,110 |
Taxes recoverable | 930,761 | 541,680 | 1,765,844 | 948,238 | |
Insurance contract assets | 12 | - | - | - | 27,999 |
Reinsurance contract assets | - | - | 51,016 | 41,012 | |
Derivative financial instruments | 24 | 73,406 | 69,545 | 116,865 | 92,345 |
Transactions with related parties | 7 | 1,596,700 | 1,775,289 | - | - |
Dividends receivable | 248,441 | 492,527 | 10,920 | - | |
Other | 468,080 | 397,550 | 916,485 | 745,273 | |
Total current assets | 18,797,661 | 17,741,023 | 57,305,659 | 53,778,870 | |
Noncurrent assets | |||||
Transactions with related parties | 7 | 4,040,811 | 3,631,865 | 54,614 | 74,154 |
Securities | 4 | 399,115 | - | 4,629,202 | 1,775,096 |
Accounts receivable | 5 | - | - | 1,782,470 | 1,734,724 |
Taxes recoverable | 8,677 | 8,677 | 542,136 | 503,368 | |
Insurance contract assets | 12 | - | - | - | 21,342 |
Reinsurance contract assets | - | - | 13,163 | 12,565 | |
Judicial deposits | 14 | 489,561 | 482,842 | 2,934,791 | 2,652,869 |
Deferred taxes | 17 | 647,902 | 374,569 | 4,098,179 | 4,327,326 |
Derivative financial instruments | 24 | 579,419 | 417,886 | 2,471,358 | 2,954,497 |
Investments in subsidiaries, associates and joint | |||||
ventures | 8 | 35,026,605 | 31,468,248 | 2,482,421 | 2,437,864 |
Property and equipment | 9 | 6,689,848 | 6,215,239 | 18,201,057 | 16,789,930 |
Intangible assets | 10 | 7,509,364 | 7,563,708 | 15,697,457 | 15,809,019 |
Right of use - leases | 11 | 2,431,582 | 2,566,017 | 3,239,481 | 3,102,204 |
Other | 272,267 | 325,010 | 538,951 | 574,704 | |
Total noncurrent assets | 58,095,151 | 53,054,061 | 56,685,280 | 52,769,662 |
Total assets 76,892,812 70,795,084 113,990,939 106,548,532
Liabilities and equity Current liabilities
Trade accounts payable | 831,270 | 803,791 | 1,950,266 | 1,761,444 | |
Derivative financial instruments | 24 | 733,214 | 637,183 | 1,216,579 | 1,083,440 |
Loans, financing and debentures | 13 | 4,923,161 | 1,745,424 | 4,779,237 | 1,712,740 |
Transactions with related parties | 7 | - | - | - | 16,860 |
Salaries, accruals and social charges | 625,481 | 628,170 | 1,431,213 | 1,248,171 | |
Tax obligations | 381,781 | 280,726 | 1,225,592 | 924,479 | |
Accounts payable for acquisitions | 17,237 | 15,668 | 519,683 | 475,207 | |
Dividends and IOE payable | 16 | 2,457,269 | 3,023,466 | 2,494,811 | 3,060,098 |
Insurance contract liabilities | 12 | - | - | 7,928,885 | 6,904,651 |
Leases | 15 | 639,130 | 616,902 | 827,084 | 760,520 |
Other | 95,445 | 69,134 | 1,212,199 | 1,324,999 | |
Total current liabilities | 10,703,988 | 7,820,464 | 23,585,549 | 19,272,609 | |
Noncurrent liabilities Derivative financial instruments | 24 | 939,897 | 1,004,181 | 1,260,741 | 1,045,045 |
Loans, financing and debentures | 13 | 39,303,192 | 38,139,109 | 44,881,499 | 44,521,391 |
Transactions with related parties | 7 | 8,984 | - | 5,422 | 4,337 |
Tax obligations | 25,211 | 26,610 | 126,576 | 130,237 | |
Accounts payable for acquisitions | 50 | 338 | 209,365 | 215,617 | |
Insurance contract liabilities | 12 | - | - | 11,945,860 | 11,789,166 |
Deferred taxes | 17 | - | - | 492,077 | 385,699 |
Provision for contingencies | 14 | 538,679 | 530,315 | 3,540,525 | 3,092,700 |
Provision for losses on investments | 8 | 930,035 | 839,321 | - | - |
Leases | 15 | 2,368,507 | 2,493,811 | 3,119,010 | 2,963,924 |
Other | 728,294 | 589,227 | 1,157,507 | 1,506,720 | |
Total noncurrent liabilities | 44,842,849 | 43,622,912 | 66,738,582 | 65,654,836 | |
Equity Capital | 16 | 15,711,360 | 15,711,360 | 15,711,360 | 15,711,360 |
Share issue costs | (253,031) | (253,031) | (253,031) | (253,031) | |
Capital reserves | 4,610,636 | 5,009,707 | 4,610,636 | 5,009,707 | |
Treasury shares | (1,823,119) | (1,828,733) | (1,823,119) | (1,828,733) | |
Income reserves | 146,337 | 146,337 | 146,337 | 146,337 | |
Retained earnings | 2,302,752 | - | 2,302,752 | - | |
Advance for future capital increase | 4,224 | 4,224 | 4,224 | 4,224 | |
Other comprehensive income | 646,816 | 561,844 | 646,816 | 561,844 | |
Total equity attributable to the Company's shareholders | 21,345,975 | 19,351,708 | 21,345,975 | 19,351,708 | |
Noncontrolling interests | - | - | 2,320,833 | 2,269,379 | |
Total equity | 21,345,975 | 19,351,708 | 23,666,808 | 21,621,087 | |
Total liabilities and equity | 76,892,812 | 70,795,084 | 113,990,939 | 106,548,532 | |
See accompanying notes. |
Statements of profit or loss
Three and Nine-month periods ended September 30, 2026 and 2025 (In thousands of Brazilian reais, unless otherwise stated)
Individual | Consolidated | ||||||||
07/01/2026 to | 01/01/2026 to | 07/01/2025 to | 01/01/2025 to | 07/01/2026 to | 01/01/2026 to | 07/01/2025 to | 01/01/2025 to | ||
Note | 09/30/2026 | 09/30/2026 | 09/30/2025 | 09/30/2025 | 09/30/2026 | 09/30/2026 | 09/30/2025 | 09/30/2025 | |
Operating revenue, net | 18 | 4,430,830 | 12,869,233 | 4,042,533 | 11,710,778 | 15,242,042 | 44,242,408 | 14,415,537 | 41,349,416 |
Operating costs | 19 | (2,902,654) | (8,578,583) | (2,753,824) | (7,952,990) | (11,089,892) | (33,305,091) | (11,054,613) | (32,355,128) |
Gross profit | 1,528,176 | 4,290,650 | 1,288,709 | 3,757,788 | 4,152,150 | 10,937,317 | 3,360,924 | 8,994,288 | |
General and administrative expenses | 20 | (381,185) | (1,096,633) | (230,847) | (838,443) | (744,096) | (2,078,208) | (532,955) | (1,588,063) |
Selling expenses | (10,604) | (30,112) | (19,813) | (5,137) | (21,764) | (66,137) | (49,689) | (33,830) | |
Equity accounting | 8 | 1,360,201 | 3,417,094 | 1,403,292 | 3,238,463 | 14,571 | 27,799 | 16,301 | 28,799 |
Other operating income (expens es), net | 21 | (62,887) | 186,237 | (57,359) | (66,386) | (283,638) | (102,879) | (46,170) | (174,988) |
Income before finance income (costs) and income and social contribution taxes | 2,433,701 | 6,767,236 | 2,383,982 | 6,086,285 | 3,117,223 | 8,717,892 | 2,748,411 | 7,226,206 | |
Finance income | 22 | 1,352,861 | 3,924,824 | 630,009 | 2,423,503 | 2,949,384 | 9,594,228 | 2,694,595 | 8,191,258 |
Finance costs | 22 | (2,473,084) | (7,497,602) | (1,714,295) | (5,434,678) | (4,352,956) | (13,491,000) | (3,543,986) | (10,974,178) |
Profit before income taxes | 1,313,478 | 3,194,458 | 1,299,696 | 3,075,110 | 1,713,651 | 4,821,120 | 1,899,020 | 4,443,286 | |
Income taxes | 17 | (36,996) | 258,294 | 174,197 | 440,864 | (347,000) | (1,156,433) | (360,893) | (790,620) |
Profit for the period | 1,276,482 | 3,452,752 | 1,473,893 | 3,515,974 | 1,366,651 | 3,664,687 | 1,538,127 | 3,652,666 | |
Profit attributable to controlling interests | 1,276,482 | 3,452,752 | 1,473,893 | 3,515,974 | 1,276,482 | 3,452,752 | 1,473,893 | 3,515,974 | |
Profit attributable to noncontrolling interests | - | - | - | - | 90,169 | 211,935 | 64,234 | 136,692 | |
Basic earnings per share (in reais) | 23 | 0.5910 | 1.5892 | 0.6679 | 1.5933 | 0.5910 | 1.5892 | 0.6679 | 1.5933 |
Diluted earnings per share (in reais) | 23 | 0.5910 | 1.5892 | 0.6679 | 1.5933 | 0.5910 | 1.5892 | 0.6679 | 1.5933 |
See accompanying notes. | |||||||||
Statements of comprehensive income
Three and Nine-month periods ended September 30, 2026 and 2025 (In thousands of Brazilian reais)
Individual | Consolidated | |||||||
07/01/2026 to 01/01/2026 to | 07/01/2025 to | 01/01/2025 to | 07/01/2026 to | 01/01/2026 to 07/01/2025 to | 01/01/2025 to | |||
09/30/2026 09/30/2026 | 09/30/2025 | 09/30/2025 | 09/30/2026 | 09/30/2026 09/30/2025 | 09/30/2025 | |||
Profit for the period 1,276,482 3,452,752 | 1,473,893 | 3,515,974 | 1,366,651 | 3,664,687 1,538,127 | 3,652,666 | |||
Other comprehensive income Cash flow hedge | (22,146) | (38,695) | (14,877) | (105,469) | (39,835) | (38,907) | (20,702) | (130,566) |
Gain/loss on insurance and reinsurance liabilities | - | - | - | - | (190,653) | 155,857 | 52,081 | (213,780) |
Unrealized gains (losses) on financial assets at fair value through OCI | - | - | - | - | 153,671 | 32,665 | (41,100) | 9,100 |
Tax effects | 7,530 | 13,156 | 5,059 | 35,859 | 28,811 | (64,643) | (2,408) | 122,901 |
Gains (losses) on changes in equity interest | - | - | - | - | - | - | 34,417 | - |
Other comprehensive income of associates and subsidiaries under the equity method | (33,390) | 110,511 | 32,106 | (142,735) | - | - | - | - |
(48,006) | 84,972 | 22,288 | (212,345) | (48,006) | 84,972 | 22,288 | (212,345) | |
Total comprehensive income 1,228,476 | 3,537,724 | 1,496,181 | 3,303,629 | 1,318,645 | 3,749,659 | 1,560,415 | 3,440,321 | |
Attributable to: Controlling interests | 1,228,476 | 3,537,724 | 1,496,181 | 3,303,629 | 1,228,476 | 3,537,724 | 1,496,181 | 3,303,629 |
Noncontrolling interests | - | - | - | - | 90,169 | 211,935 | 64,234 | 136,692 |
See accompanying notes.
Statements of changes in equity
Nine-month periods ended September 30, 2026 and 2025 (In thousands of Brazilian reais)
Attributable to the Company's controlling shareholders
Description | Capital | Premium reserve Share issue (share cos ts issue) | Premium on capital transactions | Share-based payment reserve | Treasury s hares | Legal reserve | Investment reserve | Other comprehensiv e income | Advance for future capital increase | Retained earnings Total equity | Noncontrolling interests | Total | |
Balances at December 31, 2024 | 15,711,360 | (253,031) 6,190,053 | (1,229,297) | - | 1,458,602) | 8,666 | 4,921,769 | 807,485 | 4,224 | - 24,702,627 | 1,999,241 | 26,701,868 | |
Capital transactions in subsidiaries and acquisition of | |||||||||||||
noncontrolling interests - | - | - | 31,775 | - | - | - | - | - | - | - | 31,775 | 537,040 | 568,815 |
Changes - RSU (Note 16) - | - | 14,427 | - | (14,198) | 802 | - | - | - | - | - | 1,031 | - | 1,031 |
Share-based payment (Note 16) - | - | - | - | 14,198 | - | - | - | - | - | - | 14,198 | - | 14,198 |
Profit for the period - | - | - | - | - | - | - | - | - | - | 3,515,974 | 3,515,974 | 136,692 | 3,652,666 |
Dividends and interest on equity (Note 16) - | - | - | - | - | - | - | (1,350,000) | - | - | - | (1,350,000) | (203,032) | (1,553,032) |
Share buyback - | - | - | - | - | (370,933) | - | - | - | - | - | (370,933) | - | (370,933) |
Cash flow hedge (Note 16) - | - | - | - | - | - | - | - | (69,610) | - | - | (69,610) | - | (69,610) |
Equity adjustments - | - | - | - | - | - | - | - | (14,454) | - | - | (14,454) | - | (14,454) |
reinsurance contracts - | - | - | - | - | - | - | - | (128,281) | - | - | (128,281) | - | (128,281) |
Balances at September 30, 2025 15,711,360 | (253,031) | 6,204,480 | (1,197,522) | - | (1,828,733) | 8,666 | 3,571,769 | 595,140 | 4,224 | 3,515,974 | 26,332,327 | 2,469,941 | 28,802,268 |
Balances at December 31, 2025 15,711,360 | (253,031) | 6,215,354 | (1,205,647) | - | (1,828,733) | 8,666 | 137,671 | 561,844 | 4,224 | - | 19,351,708 | 2,269,379 | 21,621,087 |
Capital transactions in subsidiaries and acquisition of noncontrolling interests - | - | - | 786,192 | - | - | - | - | - | - | - | 786,192 | (140,775) | 645,417 |
Changes - RSU (Note 16) - | - | 2,546 | - | - | - | - | - | - | - | - | 2,546 | - | 2,546 |
Profit for the period - | - | - | - | - | - | - | - | - | - | 3,452,752 | 3,452,752 | 211,935 | 3,664,687 |
Dividends and interest on equity (Note 16) - | - | - | - | - | - | - | - | - | - | (1,150,000) | (1,150,000) | (19,706) | (1,169,706) |
Share buyback - | - | - | - | - | (1,182,195) | - | - | - | - | - | (1,182,195) | - | (1,182,195) |
Cancellation of shares (Note 16.c) - | - | (1,187,809) | - | - | 1,187,809 | - | - | - | - | - | - | - | - |
Cash flow hedge (Note 16) - | - | - | - | - | - | - | - | (25,666) | - | - | (25,666) | - | (25,666) |
Equity adjustments - | - | - | - | - | - | - | - | 17,092 | - | - | 17,092 | - | 17,092 |
reinsurance contracts - | - | - | - | - | - | - | - | 93,546 | - | - | 93,546 | - | 93,546 |
Capital Capital reserves Income reserves
Net finance income (costs) from insurance and
Net finance income (costs) from insurance and
Balances at September 30, 2026 15,711,360 (253,031) 5,030,091 (419,455) - (1,823,119) 8,666 137,671 646,816 4,224 2,302,752 21,345,975 2,320,833 23,666,808
See accompanying notes.
Statements of cash flows
Nine-month periods ended September 30, 2026 and 2025 (In thousands of Brazilian reais)
Individual Consolidated
09/30/2026 | 09/30/2025 | 09/30/2026 | 09/30/2025 | |
Cash flows from operating activities Profit before income and social contribution taxes 3,194,458 | 3,075,110 | 4,821,120 | 4,443,286 | |
Adjustments to reconcile profit before taxes to cash flows from operating activities | ||||
Depreciation and amortization | 666,809 | 717,334 | 1,352,870 | 1,404,681 |
Gain on disposal of properties | (2,940) | (2,940) | (2,940) | (2,940) |
Fair value of debt | 29,509 | 603,463 | (420,340) | 740,136 |
Interest, monetary and foreign exchange differences, net | 3,916,499 | 2,620,375 | 1,681,330 | (427,586) |
Share-based payment | 77,118 | 68,195 | 77,118 | 68,195 |
Provision (reversal) for contingencies | 20,914 | (111,342) | 600,268 | 249,927 |
Equity accounting | (3,417,094) | (3,238,463) | (27,799) | (28,799) |
Income (loss) from insurance service | - | - | (8,864,333) | (6,924,900) |
Allowance for expected credit losses | 638,078 | 576,884 | 1,260,746 | 1,094,642 |
(Increase) decrease in assets and increase (decrease) in liabilities | ||||
Accounts receivable | (818,706) | (1,237,107) | (1,652,446) | (2,000,065) |
Inventories | (61,184) | (30,988) | (112,863) | 10,229 |
Taxes recoverable | (286,266) | 83,402 | (820,565) | (23,336) |
Judicial deposits | (6,817) | (36,555) | (174,972) | 253,478 |
Other assets | (363,626) | 590,738 | (504,429) | 499,554 |
Trade accounts payable | 44,736 | 126,499 | 188,822 | 267,063 |
Salaries and social charges | 64,981 | 175,598 | 230,442 | 303,390 |
Tax obligations | (20,362) | (140,742) | 288,869 | (164,532) |
Transactions with related parties | (281,170) | (2,201,814) | 3,765 | 193,038 |
Provision for contingencies | (30,945) | (49,582) | (356,956) | (704,174) |
Insurance and reinsurance assets (liabilities) | - | - | 10,250,459 | 5,876,254 |
Other liabilities | 72,181 | 176,996 | (122,569) | (314,204) |
3,436,173 | 1,765,061 | 7,695,597 | 4,813,337 | |
Payment of interest | (4,478,843) | (3,095,288) | (4,423,242) | (3,124,891) |
Payment of income and social contribution taxes | - | - | (994,041) | (896,199) |
Net cash from (used in) operating activities (1,042,670) | (1,330,227) | 2,278,314 | 792,247 | |
Cash flows from investing activities | ||||
Payment in business acquisition, net of cash acquired | - | - | - | 132 |
Cash from merger of subsidiary | - | (6) | - | - |
Proceeds from disposal of equity interest, net of cash | 714,143 | 1,225,931 | 714,143 | - |
Acquisition of equity interest | - | - | (129,200) | (1,666) |
Advance for future capital increase | (433,578) | (683,746) | - | - |
Additions to property and equipment | (879,017) | (571,631) | (2,195,432) | (2,268,589) |
Additions to intangible assets | (51,611) | (67,545) | (129,603) | (212,186) |
Acquisition of securities | (23,039,934) | (21,776,889) | (69,051,086) | (86,384,286) |
Redemption of securities | 23,529,412 | 21,581,910 | 68,216,973 | 84,526,533 |
Dividends and interest on equity received | 1,257,397 | 1,973,370 | 14,017 | 45,071 |
Net cash from (used in) investing activities | 1,096,812 | 1,681,394 | (2,560,188) | (4,294,991) |
Cash flows from financing activities | ||||
Treasury shares | (1,182,195) | (390,449) | (1,182,195) | (390,449) |
Payment of dividends and IOE | (1,594,624) | (822,278) | (1,613,420) | (1,025,557) |
Loans, financing and debentures raised | 5,485,000 | 5,985,539 | 5,485,000 | 8,115,539 |
Payment of loans, financing and debentures | (1,721,002) | (3,504,901) | (1,863,754) | (3,624,777) |
Settlement of swap | (527,088) | (380,715) | (1,021,130) | (551,698) |
Accounts payable for acquisitions | - | - | (18,045) | (56,124) |
Cash flow from (used in) financing activities | 460,091 | 887,196 | (213,544) | 2,466,934 |
Increase (decrease) in cash and cash equivalents | 514,233 | 1,238,363 | (495,418) | (1,035,810) |
Cash and cash equivalents at beginning of period | 214,163 | 408,911 | 3,705,415 | 6,570,751 |
Cash and cash equivalents at end of period | 728,396 | 1,647,274 | 3,209,997 | 5,534,941 |
See accompanying notes.
Statements of value added
Nine-month periods ended September 30, 2026 and 2025 (In thousands of Brazilian reais, unless otherwise stated)
Individual | Consolidated | |||
09/30/2026 | 09/30/2025 | 09/30/2026 | 09/30/2025 | |
Revenue | 14,076,184 | 12,437,959 | 46,565,707 | 43,160,287 |
Sales of goods, products and services | 14,301,444 | 13,011,903 | 21,634,450 | 19,903,143 |
Revenues from insurance operations | - | - | 25,676,876 | 24,260,480 |
Allowance for expected credit losses | (638,078) | (576,884) | (1,260,746) | (1,094,642) |
Other revenues | 412,818 | 2,940 | 515,127 | 91,306 |
Benefits and claims | - | - | (14,178,675) | (14,840,788) |
Expenses with benefits and redemptions | - | - | (14,178,675) | (14,840,788) |
Materials acquired from third parties | (4,952,501) | (4,224,199) | (12,129,465) | (10,332,556) |
Costs of sales | (4,506,011) | (4,109,012) | (10,652,317) | (9,581,357) |
Materials, power, third-party services and other | (425,576) | (226,529) | (876,880) | (501,272) |
Loss on/recovery of assets | (20,914) | 111,342 | (600,268) | (249,927) |
Gross value added | 9,123,683 | 8,213,760 | 20,257,567 | 17,986,943 |
Depreciation and amortization | (666,809) | (717,334) | (1,352,870) | (1,404,681) |
Net value added | 8,456,874 | 7,496,426 | 18,904,697 | 16,582,262 |
Value added received in transfer | 7,341,918 | 5,661,966 | 6,981,314 | 5,740,381 |
Equity accounting | 3,417,094 | 3,238,463 | 27,799 | 28,799 |
Finance income | 3,924,824 | 2,423,503 | 9,594,228 | 8,191,258 |
Finance income (costs) from insurance contracts | - | - | (2,640,713) | (2,479,676) |
Total value added | 15,798,792 | 13,158,392 | 25,886,011 | 22,322,643 |
Distribution of value added | (15,798,792) | (13,158,392) | (25,886,011) | (22,322,643) |
Personnel and related charges | (4,096,432) | (3,734,477) | (7,820,570) | (7,096,300) |
Salaries | (3,671,717) | (3,326,922) | (6,913,750) | (6,228,867) |
Benefits | (280,801) | (268,166) | (596,113) | (580,198) |
Unemployment Compensation Fund (FGTS) | (143,914) | (139,389) | (310,707) | (287,235) |
Taxes, charges and contributions | (535,839) | (267,284) | (3,067,507) | (2,574,487) |
Federal taxes | (210,714) | 15,563 | (2,318,638) | (1,915,636) |
State taxes | - | (191) | (32,663) | (38,175) |
Local taxes | (325,125) | (282,656) | (716,206) | (620,676) |
Debt remuneration | (7,713,769) | (5,640,657) | (11,333,247) | (8,999,190) |
Interest | (7,497,602) | (5,434,678) | (10,850,249) | (8,488,006) |
Rents | (8,217) | (8,059) | (23,970) | (78,022) |
Other | (207,950) | (197,920) | (459,028) | (433,162) |
Equity remuneration | (3,452,752) | (3,515,974) | (3,664,687) | (3,652,666) |
Interest on equity | (1,150,000) | (1,350,000) | (1,150,000) | (1,350,000) |
Dividends | - | - | (19,706) | (203,032) |
Retained profits | (2,302,752) | (2,165,974) | (2,302,752) | (2,165,974) |
Noncontrolling interests on retained profits | - | - | (192,229) | 66,340 |
See accompanying notes. | ||||
Notes to the interim financial information September 30, 2026
(In thousands of Brazilian reais, unless otherwise stated)
- Operations
Rede D'Or São Luiz S.A. (the "Company" or "Parent Company" and jointly with its subsidiaries "Rede D'Or" or "Group"), headquartered at Rua Francisco Marengo, 1.312, in the city and state of São Paulo, is engaged in the rendering of hospital services, offering assistance and hospitality concepts, creating medical and diagnostic excellence centers and generating medical knowledge and experience that ensure security to customers, either doctors, patients or healthcare plans.
Through its subsidiaries and associates, the Company operates in the health (health and dental insurance, administrative services only (ASO) health and dental plans, and health and wellness solutions), life insurance, private pension, and asset management segments.
Rede D'Or operates in the states of Rio de Janeiro, São Paulo, Pernambuco, Maranhão, Bahia, Sergipe, Paraná, Ceará, Minas Gerais, Mato Grosso do Sul, Paraíba, Alagoas, Pará and the Federal District, with 73 own hospitals in operation and over 20 projects under development, in addition to oncology and radiotherapy clinics and laboratories. Currently, the Group has 10,585 hospital beds in total.
The first hospital unit, Hospital Barra D'Or, was opened in 1998, and Hospital Copa D'Or and Hospital Quinta D'Or were opened in 2000 and 2001, respectively. Since 2004, strategic partnerships have been made with other hospitals, thus increasing its range of expertise and reaching other areas in Rio de Janeiro. Also through partnerships and acquisitions, Rede D'Or started operations in the state of Pernambuco in 2007; in the states of Maranhão and Bahia in 2018; in the state of Sergipe in 2019; in the states of Paraná and Ceará in 2020; in the states of Minas Gerais, Mato Grosso do Sul and Paraíba in 2021; and in the state of Alagoas in 2022.
In December 2022, the business combination between the Company and Sul América S.A. was completed through the merger of Sul América S.A. into Rede D'Or. As a result of the merger, Sul América S.A. was dissolved and succeeded by Rede D'Or as regards all its assets, rights and obligations, and Rede D'Or became the parent company of Sul América Group ("SASA" or "Sul América" - comprising the subsidiaries, associates and investment funds remaining from the merger of Sul América S.A.).
Seasonality
There are no significant seasonal effects on the Company's operations; however, a smaller volume of customers and, consequently, of claims in the insurance and health insurance businesses, is generally observed in December, January and February due to year-end
celebrations and vacation period, and a larger volume of customers is observed in winter.
Notes to the interim financial information September 30, 2026
(In thousands of Brazilian reais, unless otherwise stated)
- Accounting policies
This individual and consolidated interim financial information was prepared in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting, issued by the Brazilian Accounting Pronouncements Committee ("CPC"), and in accordance with IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and is presented in accordance with the rules issued by the Brazilian Securities and Exchange Commission ("CVM") applicable to the preparation of Quarterly Information Form (ITR). The statements of value added are presented as supplementary information for IFRS purposes.
The accounting policies as well as estimates and critical accounting judgments adopted by the Group in this interim financial information are consistent with those adopted in the financial statements for the year ended December 31, 2025, disclosed on February 25, 2026.
Profit or loss for the nine-month period ended September 30, 2026 are not necessarily indicative of the profit or loss that may be expected for the full year ending December 31, 2026. The interim financial information and related notes do not include all information and disclosures required for the annual financial statements. As such, this interim financial information must be read together with the audited annual financial statements as of December 31, 2025.
Authorization to complete the preparation of this interim financial information was provided by the Company management on November 11, 2026.
The individual and consolidated interim financial information includes the operations of the Company and its subsidiaries, as presented in Note 8. Additionally, as of September 30, 2026, the Company holds investments in funds-of-one that are fully consolidated.
- Atlântica Hospitais transactions
On August 16, 2024, the Company entered into a partnership with Atlântica Hospitais e Participações S.A. ("Atlântica Hospitais") - a company focused on investments in hospitals and an indirect subsidiary of Bradseg Participações S.A., which in turn is the parent of Bradesco Seguros Group - for the creation of the new hospital network "Atlântica D'Or" (Pacífico Holding Imobiliária Hospitalar S.A. and Pacífico Operações Hospitalares S.A.). The Partnership consists of a corporate association for investments in, construction, development and operation of hospitals, with Rede D'Or holding a 50.01% interest and acting as the hospital operator and controlling shareholder of the new Atlântica D'Or hospital network, and Atlântica Hospitais holding a 49.99% interest. The Partnership encompasses all investments and assets, including real estate assets, related to the hospitals
Notes to the interim financial information September 30, 2026
(In thousands of Brazilian reais, unless otherwise stated)
On September 1, 2025, the Company entered into an investment, purchase and sale and other covenants agreement with Atlântica Hospitais for the contribution of assets and liabilities of Hospital Glória D'Or and SPE IH Glória D'Or, located in the city of Rio de Janeiro, to the Atlântica D'Or hospital network, with Rede D'Or holding a 50.01% interest and Atlântica Hospitais holding a 49.99% interest. On January 30, 2026, the Company completed the contribution of the assets and liabilities of Hospital Glória D'Or and SPE IH Glória D'Or to Atlântica D'Or. The Company received R$452,037 in connection with the acquisition of the shares corresponding to a 49.99% equity interest.
On November 10, 2025, the Company entered into an investment, purchase and sale and other covenants agreement with Atlântica Hospitais for the contribution of the hospital operations of Maternidade São Luiz Star ("Maternidade Star"), located in the city of São Paulo, to the Atlântica D'Or hospital network, with Rede D'Or holding a 50.01% interest and Atlântica Hospitais holding a 49.99% interest. The transaction does not include the real property in which Maternidade Star's activities are conducted, which will continue to be wholly owned by the Rede D'Or group. On February 26, 2026, the Company completed the closing of the contribution of the assets and liabilities of Maternidade Star to Atlântica D'Or. The Company received R$224,326 in connection with the acquisition of the shares corresponding to a 49.99% equity interest.
On May 26, 2026, the Company entered into an investment, purchase and sale and other covenants agreement with Atlântica Hospitais and Atlântica Empreendimentos Imobiliários Ltda. ("Atlântica") for the contribution to the Atlântica D'Or hospital network of properties located in the district of São Conrado, in the city of Rio de Janeiro, State of Rio de Janeiro, where Hospital São Conrado D'Or will be developed and operated, with Rede D'Or holding a 50.01% interest and Atlântica holding a 49.99% interest. On July 13, 2026, the Company completed the closing of the contribution of certain properties owned by Rede D'Or to Atlântica D'Or. The consideration of R$60,582, corresponding to the acquisition of a 49.99% interest, will be paid in full by January 2027.
On September 2, 2026, the Company entered into an investment, purchase and sale and other covenants agreement with Atlântica Hospitais for the contribution of Hospital Biocor, located in the city of Nova Lima, in the Belo Horizonte metropolitan area, State of Minas Gerais ("Hospital Biocor"), to the "Atlântica D'Or" hospital network, a corporate partnership in which Rede D'Or, its hospital operator, holds a 50.01% interest and Atlântica holds a 49.99% interest. The Company will receive approximately R$130,000, to be adjusted based on changes in the Interbank Deposit Certificate (CDI) rate through the closing of the transaction. Completion of the transaction is subject to the fulfillment of certain conditions precedent customary for transactions of this nature, including the applicable regulatory approvals.
On September 16, 2026, Atlântica D'Or completed the acquisition of certain real estate assets intended for the construction and future operation of a hospital in the city of Jundiaí, State of São Paulo. Rede D'Or will be responsible for managing the unit, and the existing ownership structure of the partnership will be maintained, with Rede D'Or holding a 50.01% interest and Atlântica holding a 49.99% interest.
Notes to the interim financial information September 30, 2026
(In thousands of Brazilian reais, unless otherwise stated)
As of September 30, 2026, the partnership encompasses six hospitals in operation (São Luiz Guarulhos, São Luiz Alphaville, Macaé D'Or, Hospital São Luiz Campinas, Hospital Glória D'Or and Maternidade São Luiz Star) and five other projects under development (located in Ribeirão Preto, Taubaté, Sorocaba, São Conrado and Jundiaí).
- Cash and cash equivalents and s ecurities
- Cash and cash equivalents
Individual Consolidated
09/30/2026
12/31/2025
09/30/2026
12/31/2025
Cash and cash equivalents Cash and banks
9,511
13,626
46,459
63,526
Marketable securities
718,885
200,537
3,163,538
3,641,889
Cash and cash equivalents
728,396
214,163
3,209,997
3,705,415
Marketable securities classified as cash equivalents have maturities of less than three months from the date of acquisition and have an insignificant risk of changes in value.
- Securities
Securities are broken down in the table below, which shows their respective classifications, curve value and market value, as well as the contractual average rates:
Fair value through profit
Individual
or loss Amortized cost
09/30/2026
12/31/2025
Description
Market value/ carrying
amount
Curve value/carrying
amount Market value
Average interest rate (a)
Total
Average interest rate (a)
Total
Fixed income securities - corporate bonds
6,584,928
6,984,043
7,105,528
Bank deposit certificates
Floating rate CDI %
Debentures
Floating rate CDI +
6,462,250
-
399,115
-
-
399,115
100.83% CDI
CDI+4.00% p.a.
6,462,250
399,115
101.68% CDI
-
6,965,003
-
Financial bills
Floating rate CDI +
122,678
-
-
CDI+0.14% p.a.
122,678
CDI+0.27% p.a.
84,556
Floating rate CDI %
Fixed income securities -
-
-
-
-
-
105.00% CDI
55,969
government securities
1,964,323
1,964,323
1,304,929
Financial treasury bills National treasury bills
1,512,709
-
-
SELIC
1,512,709
SELIC
1,304,929
Fixed rate
451,614
-
-
14.03% p.a.
451,614
-
-
Investment fund shares
Investment fund shares - other than funds-of-one
217,241
217,241
-
-
-
217,241
217,241
-
26
26
9,165,607
8,410,483
Current
8,766,492
Current
8,410,483
Noncurrent
399,115
Noncurrent
-
Fair value through profit or loss
Market value/
Fair value through other
comprehensive income Amortized cost
Market
value/ Curve
Consolidated
09/30/2026 Average rate 12/31/2025
Description Carrying amount Curve value
Carrying
amount
value/carrying
amount
Market
value
Average
interest rate(a)
Total
interest (a)
Total
Fixed income securities - corporate
bonds 11,465,367 897,378
880,223
399,115
399,115
12,744,705
14,199,719
Bank deposit certificates
Floating rate CDI +
6,199
-
-
-
-
CDI+0.26% p.a.
6,199
CDI+0.26% p.a.
19,721
Floating rate CDI % Debentures
7,582,979
-
-
-
-
100.82% CDI
7,582,979
101.69% CDI
9,715,947
Fixed rate
78,242
-
-
-
-
13.7% p.a.
78,242
12.79% p.a.
73,366
Floating rate CDI +
1,011,748
98,430
99,517
399,115
399,115
CDI+2.12% p.a.
1,510,380
CDI+1.72% p.a.
1,204,552
Floating rate CDI %
16,660
-
-
-
-
106.2% CDI
16,660
116.96% CDI
3,237
Floating rate IPCA
818,909
-
-
-
-
IPCA+8.08% p.a.
818,909
IPCA+7.29% p.a.
580,135
Floating rate IGP-M Financial bills
-
110,258
98,004
-
-
IGPM+5.84% p.a.
98,004
IGPM+5.84% p.a.
95,522
Fixed rate
9,611
-
-
-
-
14.43% fixed rate
9,611
-
-
Floating rate CDI +
1,768,808
-
-
-
-
CDI+0.29% p.a.
1,768,808
CDI+0.47% p.a.
1,683,459
Floating rate CDI %
68,137
-
-
-
-
101.73% CDI
68,137
108.99%CDI
116,001
Floating rate IPCA
-
658,253
651,895
-
-
IPCA+8.17% p.a.
651,895
IPCA+8.17% p.a.
610,887
Promissory notes
Mortgage-backed Securities ("CRI")
6,346
30,437
30,807
-
-
CDI+1.57% p.a.
37,153
CDI+1.54% p.a.
40,872
CRI Fixed rate
10,486
-
-
-
-
15.33% p.a.
10,486
15.86% p.a.
1,213
Floating rate CDI +
14,162
-
-
-
-
CDI+1.64% p.a.
14,162
-
-
Time deposits with special guarantee (DPGE)
73,080
-
-
-
-
CDI+0.4% p.a.
73,080
CDI+0.49% p.a.
54,807
Fixed income securities -government securities
18,914,091
3,827,461
3,793,114
3,959,065
3,838,880
26,666,270
20,249,429
Financial treasury bills National treasury bills
16,290,397
17,135
17,167
-
-
SELIC
16,307,564
SELIC
13,381,692
Fixed rate
National treasury notes
2,269,774
-
-
-
-
13.98% p.a.
2,269,774
13.43% p.a.
600,028
Series F - Fixed rate
336
19,560
18,478
-
-
9.27% p.a.
18,814
9.27% p.a.
19,012
Series B - Floating rate IPCA
39,067
3,463,354
3,436,735
74,493
66,459
IPCA+7.2% p.a.
3,550,295
IPCA+6.42% p.a.
1,903,885
Series C - Floating rate IGP-M
78,057
327,412
320,734
1,735,056
1,622,905
IGPM+5.94% p.a.
2,133,847
IGPM+5.94% p.a.
2,164,767
Fixed income securities abroad
236,460
-
-
2,149,516
2,149,516
13.86% p.a.
2,385,976
13.86% p.a.
2,180,045
Variable income securities
212,268
212,268
227,711
Shares
212,268
-
-
-
-
-
212,268
-
227,711
Investment fund shares
4,442,465
4,442,465
3,949,500
Fixed income, private equity and multimarket investment fund
shares
4,417,966
-
-
-
-
-
4,417,966
-
3,922,215
Equity investment fund shares
24,499
-
-
-
-
-
24,499
-
27,285
Other investments
10,642
-
-
-
-
- 10,642
- 3,820
44,076,350
38,630,179
Current 39,447,148
Current 36,855,083
Noncurrent 4,629,202
Noncurrent 1,775,096
(a) For securities classified as at fair value through profit or loss (FVPL), average market rates are used. For those classified as at fair value through other comprehensive income (FVOCI) and at amortized cost, acquisition rates (yield curve) are used for interest accrual purposes, while assets classified as FVOCI are also marked to market for fair value measurement purposes.
- Cash and cash equivalents
- Accounts receivable
Individual Consolidated
Description Note 09/30/2026 12/31/2025 09/30/2026 12/31/2025
Accounts receivable - hospital services
5.1
5,402,603
5,312,008
9,078,737
8,689,373
Other accounts receivable
5.2
-
-
3,215,082
3,212,746
5,402,603 5,312,008 12,293,819 11,902,119
Current
5,402,603
5,312,008
10,511,349
10,167,395
Noncurrent
-
-
1,782,470
1,734,724
- Hospital services
Trade accounts receivable comprise receivables from healthcare companies and individuals, as follows:
Individual Consolidated
09/30/2026
12/31/2025
09/30/2026
12/31/2025
Accounts receivable from health insurance and health plans
6,452,597
6,282,646
10,654,321
10,236,070
Accounts receivable from individuals Allowance for expected credit losses and
86,737
116,415
176,740
213,927
provision for disallowances (1,136,731)
(1,087,053)
(1,752,324)
(1,760,624)
5,402,603
5,312,008
9,078,737
8,689,373
Changes in provision for disallowances and allowance for expected credit losses
Individual Consolidated 09/30/2026 09/30/2025 09/30/2026 09/30/2025
Balance at beginning of period
(1,087,053)
(1,114,970)
(1,760,624)
(1,873,401)
(Recognition)/reversal of
provision for disallowances and
allowance for expected credit losses
(638,078)
(576,884)
(1,231,313)
(1,072,512)
Write-offs (a)
573,946
550,640
1,239,613
1,105,628
Provision arising from the transfer of
assets (b)
14,454
16,533
-
-
Transfer to assets available for sale
-
-
-
53,342
Balance at end of period
(1,136,731)
(1,124,681)
(1,752,324)
(1,786,943)
Write-offs include the derecognition of uncollectible amounts and elimination of accepted disallowances among Group companies.
Transfer of assets from Hospital Maternidade São Luiz Star in 2026 and Hospital São Luiz Campinas in 2025.
At September 30, 2026 and December 31, 2025, the aging list of trade accounts receivable was as follows:
1 - 31 -
Individual
61 -
Past due 91 -
121 -
181 -
360 -
Total Falling due 30 days 60 days 90 days 120 days 180 days 360 days 720 days
09/30/2026 6,539,334
4,466,008
154,429
123,979
131,966 202,758
251,852
544,866
663,476
12/31/2025 6,399,061
4,263,759
149,692
162,354
149,863 197,343
246,512
533,617
695,921
1 - 31 -
Consolidated
61 -
Past due 91 -
121 -
181 -
360 -
Total Falling due 30 days 60 days 90 days 120 days 180 days 360 days 720 days
09/30/2026 10,831,061
6,910,406
448,892
203,026
246,616
232,753
407,508
1,012,196 1,369,664
12/31/2025 10,449,997
6,265,931
598,516
298,737
267,530
234,563
423,324
900,188 1,461,208
The Company's revenues arise from the provision of hospital services, including the use of medicines and hospital materials. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably
measured, i.e. upon rendering of medical services at an amount that reflects the consideration to which an entity expects to be entitled in exchange for providing services to a customer.
Changes in provision for disallowances and allowance for expected credit losses
The provision for disallowances and allowance for expected credit losses are presented reducing the balance of accounts receivable and recognized at an amount deemed sufficient by management to cover any expected losses on the realization of amounts billed.
The Company's criterion to recognize a provision for disallowances is to annually analyze the performance of notes overdue between 360 to 720 days, a period deemed sufficient for exhausting the collection process. The percentage reached is applied to the gross revenue recorded and recognized as a provision in current profit or loss, reflecting management's best expectation based on the analyzed history. The analysis is made individually by cash-generating unit, as well as the percentage recorded as a provision for disallowances in the year.
As a criterion for the recognition of an allowance for expected credit losses, an individual analysis of receivables is performed to identify specific counterparty risks. If necessary, an allowance for expected credit losses is recorded for the partial or total balance of
receivables outstanding of these customers.
5.2.
Other accounts receivable
Consolidated
Description
Note
09/30/2026
12/31/2025
Other operating receivables
5.2.1
2,105,337
1,996,059
Consideration receivable - ASO health plans
5.2.2
938,341
1,067,960
Other (a)
171,404
148,727
3,215,082
3,212,746
Current
1,432,612
1,478,022
Noncurrent
1,782,470
1,734,724
(a) This balance is represented mainly by receivables related to securities obligations and receivables not directly related to insurance operations, in subsidiaries that operate in this industry.
Other operating receivables
Consolidated
09/30/2026
12/31/2025
Receivables from FCVS - SFH
Principal (Note 5.2.1.1)
1,972,509
1,957,587
Impairment (Note 5.2.1.1)
(221,281)
(221,281)
Frozen funds (a)
144,741
102,802
Other (b)
209,368
156,951
Total
2,105,337
1,996,059
Current
323,870
264,847
Noncurrent
1,781,467
1,731,212
5.2.1.1. Receivables from FCVS - SFH
Consolidated
Description
09/30/2026
Balance of receivables FCVS-SFH at 12/31/2025
1,957,587
Additions
154,783
Write-offs
(139,861)
Balance of receivables FCVS-SFH at 09/30/2026
1,972,509
Balance of impairment at 09/30/2026
(221,281)
Closing balance net of impairment at 09/30/2026
1,751,228
Current
95,070
Noncurrent
1,656,158
These refer to funds frozen in bank accounts and investment funds related to lawsuits.
This balance is mainly represented by advances to suppliers.
Consolidated
Description
12/31/2025
Balance of receivables FCVS-SFH at 12/31/2024
2,028,967
Additions
216,048
Write-offs
(287,428)
Balance of receivables FCVS-SFH at 12/31/2025
1,957,587
Balance of impairment at 12/31/2025
(221,281)
Closing balance net of impairment at 12/31/2025
1,736,306
Current
99,829
Noncurrent
1,636,477
As at September 30, 2026, there are lawsuits in progress related to the Housing Financial System (SH/SFH) in which the Company has been summoned. Such lawsuits may give rise to future cash disbursement with the corresponding request for reimbursement to Caixa Econômica Federal (CAIXA), manager of the Wage Variation Compensation Fund (FCVS). In the cases in which the lawsuit is in the provisional enforcement phase to avoid early disbursement in cases for which decisions are not final and unappealable, the Company pledges in court surety bond policies. As of September 30, 2026, the total amount secured by surety bonds was R$1,126,315 (R$1,123,206 as of December 31, 2025). The SH/HFS was established by article 14 of Law No. 4380/1964 and, since 1967, has been guaranteed by the FCVS. Insurance companies have lawsuits filed against them because they are mischaracterized as representatives of the FCVS, which is the role of CAIXA, the manager of that Fund. In view of this role of FCVS representative in lawsuits, the insurance companies, which are the illegitimate parties, are entitled to receive reimbursements for all incurred expenditures. Law No. 12409/2011, amended by Law No. 13000/2014, as well as the CCFCVS Resolution No. 364 of March 28, 2014, expressly establish the responsibility of FCVS, through its manager CAIXA, for all lawsuits relating to the SH/SFH's public policy. Currently, insurance companies are reimbursed by the FCVS for payments made in connection with SH/SFH-related lawsuits, based on the criteria established by CCFCVCS Resolution No. 448/2019 and restated by reference to the variation of the Referential Rate ("TR") between the date of payment of each expense and the date of effective reimbursement.
Consideration receivable - ASO health plans
Administrative service only (ASO) health plans are plans in which the Company administers medical and hospital expenses on behalf of its customers, and is fully reimbursed by the customers, recording only its administration fee as revenue. The amounts related to consideration receivable by maturity are as follows:
Consolidated
09/30/2026
12/31/2025
Falling due
Falling due from 1 to 30 days
851,393
950,854
Falling due from 31 to 60 days
40,255
36,247
Falling due from 61 to 180 days
655
16,111
Total falling due
892,303
1,003,212
Past due
Past due from 1 to 30 days
43,239
50,711
Past due from 31 to 60 days
1,224
14,617
Past due from 61 to 180 days
3,574
1,018
Past due from 181 to 365 days
352
854
Past due for more than 365 days
3,700
3,100
Total
52,089
70,300
Provision for impairment
(6,051)
(5,552)
Total past due
46,038
64,748
Total unearned premiums
944,392
1,073,512
Total provision for impairment
(6,051)
(5,552)
Total
938,341
1,067,960
- Hospital services
- Inventories
Individual Consolidated
09/30/2026
12/31/2025
09/30/2026
12/31/2025
Medicines
231,595
190,064
464,028
412,321
Special materials
153,830
141,241
328,619
293,537
Disposable materials
121,016
119,507
280,475
298,194
Consumables
39,205
42,654
101,428
93,786
Laboratory materials
9,390
10,022
32,613
39,570
Surgical sutures
8,390
9,176
16,310
18,065
Dressing room materials
4,976
5,035
15,729
14,923
Food stuff
6,354
6,817
11,316
12,431
Other
8,026
3,262
25,517
13,283
582,782
527,778
1,276,035
1,196,110
- Transactions with related parties
Significant related-party transactions
The nature of significant related-party transactions is summarized below:
Leases - the Company leases properties owned by the controlling shareholders, namely: properties of the hospitals Copa D'Or and Quinta D'Or, and the property of the administrative unit. Leases are at market value and generated an expense in profit or loss for the period ended September 30, 2026 of R$28,748 (R$21,845 at September 30, 2025), referring to interest and amortization of rights of use. Leases are annually restated by reference to the Extended Consumer Price Index (IPCA).
Trans fers of funds between companies - to enhance the operations of certain investees and provide funds for expansion and/or acquisitions, management transfers funds between Group companies under current account remittance agreements entered into between the parties. These balances are substantially eliminated in the consolidated financial statements.
Shared services - these are centralized services rendered by the parent company, Rede D'Or, such as legal assistance, marketing, accounting, treasury, accounts payable and accounts receivable, which are shared among the other entities of the Group based on apportionment criteria that take into consideration the contribution of each entity to the consolidated gross revenue.
Debentures - certain subsidiaries issued nonconvertible debentures, which were acquired by the parent company. These debentures are intended to provide funds to the investees for investment in operations and expansion.
Book-entry commercial papers- certain subsidiaries carried out a private placement of book-entry nonconvertible commercial papers, in specific cases, convertible into equity interests, with all of these commercial papers being acquired by the parent company. These commercial papers are intended to provide funds to the investees for investment in operations and expansion.
Revenues and accounts receivable partially arise from commercial transactions conducted in the ordinary course of business relating to medical care provided to members of Sul América plans. These transactions have reference tables by type of service provided by the Company with Sul América and the maturities of these services are stipulated in a contract entered into between the parties.
In addition to the balances presented in the tables below, the Parent Company and subsidiary Rede D'Or Finance carried out four debenture issue and purchase transactions: (i) on January 17, 2018, subsidiary Rede D'Or Finance issued senior notes totaling US$500,000 thousand, and at the same time, the Parent Company issued debentures (10th issue), which were partially acquired by other investors and by subsidiary Rede D'Or Finance (Note 13); (ii) on January 22, 2020, subsidiary Rede D'Or Finance carried out the second issue of senior notes, in the total amount of US$850,000 thousand. On February 13, 2020, Rede D'Or Finance reopened the second issue of senior notes and issued an additional US$350,000 thousand in notes with the same characteristics as the initial issue. In addition, on April 17, 2020, the Parent Company issued debentures (17th issue - 1st series), which were acquired by subsidiary Rede D'Or Finance; (iii) on September 9, 2025, subsidiary Rede D'Or Finance carried out its third issue of senior notes, for a total amount of US$500,000 thousand. In addition, on September 30, 2025, the Parent Company issued debentures (37th issue), which were acquired by subsidiary Rede D'Or Finance. The respective debentures were offered through placement efforts abroad, in accordance with the applicable legislation; and (iv) on April 28, 2026, subsidiary Rede D'Or Finance completed its fourth issue of senior notes, in the total amount of US$500,000 thousand. In addition, on May 26, 2026, the Parent Company issued debentures (40th issue), which were acquired by subsidiary Rede D'Or Finance. The respective debentures were issued through private placement efforts abroad, in accordance with the applicable law.
Balances with related parties
Individual
09/30/2026
12/31/2025
09/30/2025
Current
Noncurrent Noncurrent
Current
Noncurrent
Company
assets
assets liabilities
Profit or loss
assets
assets
Profit or loss
P&L
Debentures Norte D'Or (g)
23,743
-
-
3,984
27,506
-
5,633
3,515
Debentures São Lucas (h)
499,594
-
-
60,776
427,570
-
50,492
31,922
Debentures Hospital Nossa Senhora das Neves (c)
165,703
-
-
27,052
354,236
-
57,869
42,227
Debentures Biocor (d)
-
-
-
8,446
108,177
-
14,727
10,016
Debentures São Carlos (f)
156,244
-
-
18,126
131,552
-
17,847
12,029
Debentures Proncor (i)
333,105
-
-
39,353
259,139
-
26,059
15,607
Debentures Acreditar (j)
54,323
-
-
6,577
47,746
-
21,720
15,076
Debentures Onco Dor (k)
-
303,043
-
36,690
266,353
-
31,353
19,573
Debentures Oncologistas (m)
8,929
365,792
-
49,285
26,790
365,792
27,028
9,535
Debentures São Rafael (n)
5,728
270,000
-
31,629
17,092
270,000
17,092
6,763
Debentures Cia Saúde (o)
55,271
1,000,000
-
111,907
15,579
1,000,000
15,579
-
Debentures Mederi (p)
196,312
-
-
17,813
-
-
-
-
Book-entry commercial papers Onco Star SP (e)
-
1,755,154
-
177,785
-
1,553,594
198,120
141,725
Book-entry commercial papers Cehon (l)
97,748
-
-
11,834
85,913
-
10,113
6,313
Shared services
Medise Medicina Diagnóstico e Serviços Ltda.
-
-
-
11,121
-
-
14,987
11,564
Hospital Esperança S.A.
-
-
-
39,884
-
-
51,006
37,751
Hospital São Marcos S.A.
-
-
-
4,775
-
-
8,046
6,419
Hospital Norte D'Or de Cascadura S.A.
-
1,453
-
8,766
-
-
11,768
10,062
J. Badim S.A.
-
26,987
-
2,320
-
25,786
2,917
2,711
Oncologia D'Or S.A.
-
10,829
-
90,473
-
16,912
106,585
72,609
Hospital Fluminense S.A.
-
-
-
19,371
-
-
24,405
16,064
H. Integrados da Gávea ("Clínica São Vicente")
-
-
-
14,817
-
-
20,732
14,769
Hospital Alpha-Med LTDA.
-
-
-
4,783
-
-
5,275
3,865
Hospital UDI
-
-
-
12,812
-
-
18,693
15,155
Onco Star SP
-
3,384
-
30,621
-
3,650
35,502
26,854
DF Star
-
-
-
24,313
-
-
31,572
20,494
Samer
-
-
-
7,087
-
-
9,072
6,887
São Lucas
-
1,765
-
15,760
-
1,908
20,030
14,965
São Rafael
-
4,675
-
38,099
-
8,836
52,448
35,776
Hospital Santa Cruz
-
-
-
12,149
-
-
17,374
12,451
Hospital Aliança
-
-
-
23,765
-
-
30,264
22,146
São Carlos
-
914
-
9,270
-
2,882
12,509
7,977
Cárdio Pulmonar
-
-
-
13,622
-
-
20,066
15,796
Hospital Brasil Mauá
-
-
-
12,450
-
-
16,847
12,585
Hospital Balbino
-
-
-
2,600
-
-
3,968
2,615
Biocor H. de Doenças Cardiovasculares ("Biocor")
-
-
-
8,970
-
1,634
13,103
9,029
Proncor Unidade Intensiva Cardiorespiratória
-
1,154
-
4,439
-
1,247
5,747
3,725
Hospital Nossa Senhora das Neves
-
1,309
-
12,295
-
2,323
16,113
11,295
Hospital Novo Atibaia
-
-
-
11,751
-
-
16,121
9,208
Hospital Memorial Arthur Ramos
-
-
-
9,242
-
-
13,091
8,314
Hospital Guarulhos
-
2,173
-
18,263
-
20,042
18,697
9,200
Hospital Alphaville
-
2,250
-
18,499
-
19,940
18,928
7,056
Hospital Macaé
-
841
-
7,717
-
9,014
8,795
5,995
Hospital Campinas
-
2,390
-
21,035
-
5,594
16,598
9,595
Maternidade Star
-
1,391
-
10,072
-
-
-
-
Glória D'Or
-
2,247
-
13,121
-
-
16,041
12,917
Other
-
2,713
-
52,655
-
5,083
69,281
49,017
JMJB Diagnósticos e Serviços Hospitalares S.A. (a)
-
8,610
-
-
-
10,609
-
-
J. Badim S.A. (a)
-
7,846
-
-
-
7,308
-
-
Rede D'Or Finance
-
263,891
-
-
-
263,891
-
-
Other
-
-
8,984
29,253
7,636
35,820
32,800
22,832
1,596,700
4,040,811
8,984
1,217,427
1,775,289
3,631,865
1,253,013
841,999
Balances with related parties
Consolidated
09/30/2026 12/31/2025 09/30/2025
Company
Noncurrent assets
Noncurrent liabilities
Profit or loss
Noncurrent assets
Current liabilities
Noncurrent liabilities
Profit or loss
P&L
Debentures Biocor (d)
-
-
(313)
-
16,860
-
(2,629)
(1,883)
Shared services
J. Badim S.A.
26,987
-
2,320
25,786
-
-
2,917
2,711
New Surgical Materiais Cirúrgicos (a)
-
-
-
21,523
-
-
-
-
JMJB Diagnósticos e Serviços Hospitalares
S.A.
8,024
-
-
10,609
-
-
-
-
J Badim S.A. (a)
8,762
-
-
8,221
-
-
-
-
JM&AM Empreendimentos Imobiliários S.A. (b)
-
-
28,748
370
-
-
31,294
21,845
Other
10,841
5,422
-
7,645
-
4,337
164
150
54,614
5,422
30,755
74,154
16,860
4,337
31,746
22,823
Transfers of funds for acquisition of companies, properties, expansion of operations, among others. These balances are substantially eliminated in the consolidated financial statements.
Lease of properties owned by the controlling shareholders of Rede D'Or.
On December 18, 2025, Hospital Nossa Senhora das Neves conducted the eighth private issue of nonconvertible, single-series, registered debentures in the amount of R$212,260, maturing on December 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit
Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On January 2, 2026, Hospital Nossa Senhora das Neves conducted the ninth private issue of nonconvertible, single-series, registered debentures in the amount of R$146,251, maturing on December 30, 2026. The debentures may be fully or partially
subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.90% p.a. On March 16, 2026, the debenture was early settled, with payment of interest and principal up to that date, plus yield. There are no guarantees for the debentures.
On December 19, 2023, Biocor conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R$33,691, initially maturing on December 19, 2024; however, this term was extended to December 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. On June 23, 2026, the debenture was early settled, with payment of interest and principal up to that date, plus yield. There are no guarantees for the debentures.
On October 10, 2025, Biocor conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R$13,000, maturing on October 10, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. On June 23, 2026, the debenture was early settled, with payment of interest and principal up to that date, plus yield. There are no guarantees for the debentures.
On February 6, 2026, Biocor conducted the eighth private issue of nonconvertible, single-series, registered debentures
in the amount of R$36,200, maturing on February 10, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. On June 23, 2026, the debenture was early settled, with payment of interest and principal up to that date, plus yield. There are no guarantees for the debentures.
On May 11, 2026, Biocor conducted the ninth private issue of nonconvertible, single-series, registered debentures in the amount of R$35,000, maturing on May 10, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or.
Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. On June 23, 2026, the debenture was early settled, with payment of interest and principal up to that date, plus yield. There are no guarantees for the debentures.
On December 29, 2023, Onco Star SP Oncologia Ltda. carried out a private placement of book-entry convertible commercial papers, without security interest or collateral security system, in a single series, of first issue, in the amount of R$1,082,544, maturing on December 29, 2030. The commercial papers may be fully or partially subscribed until the maturity date by Rede D'Or. Commercial papers not subscribed after this period will be automatically canceled. The commercial papers earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
On December 29, 2024, Onco Star SP Oncologia Ltda. carried out a private placement of book-entry convertible commercial papers, without security interest or collateral security system, in a single series, of second issue, in the amount of R$150,000, maturing on December 29, 2030. The commercial papers may be fully or partially subscribed until the maturity date by Rede D'Or. Commercial papers not subscribed after this period will be automatically canceled. The commercial papers earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
On March 31, 2026, Onco Star SP Oncologia Ltda. carried out the third private placement of book-entry convertible commercial papers, without security interest or collateral security system, in a single series, of third issue, in the amount of R$180,000, maturing on December 29, 2030. The commercial papers may be fully or partially subscribed until the maturity date by Rede D'Or. Commercial papers not subscribed after this period will be automatically canceled. The commercial papers earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
On May 20, 2025, São Carlos conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R$32,862, maturing on May 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On January 15, 2026, São Carlos conducted the eighth private issue of nonconvertible, single-series, registered debentures in the amount of R$132,111, maturing on January 20, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On June 5, 2026, São Carlos conducted the ninth private issue of nonconvertible, single-series,
registered unsecured debentures in the amount of R$159,000, maturing on June 10, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. As of September 30, 2026, R$5,000 had been subscribed. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the variation of the DI (Interbank Deposit) rate plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On February 6, 2025, Norte D'Or conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R$17,343, initially maturing on February 6, 2026; however, this term was extended to February 6, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. until April 10, 2025 and 10.03% p.a. from April 10, 2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On April 30, 2025, Norte D'Or conducted the eighth private issue of nonconvertible, single-series, registered debentures in the amount of R$5,430, initially maturing on October 30, 2025; however, this term was extended to April 30, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of
the CDI (Interbank Deposit Certificate) plus 10.03% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On March 13, 2025, São Lucas conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R$15,000, maturing on March 27, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On May 13, 2025, São Lucas conducted the eighth private issue of nonconvertible, single-series, registered debentures in the amount of R$52,176, maturing on May 13, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On May 20, 2025, São Lucas conducted the ninth private issue of nonconvertible, single-series, registered debentures in the amount of R$142,403, maturing on May 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On July 20, 2025, São Lucas conducted the tenth private issue of nonconvertible, single-series, registered debentures in the amount of R$20,000, maturing on July 20, 2026; however, this term was extended to July 20, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On December 9, 2025, São Lucas conducted the eleventh private issue of nonconvertible, single-series, registered debentures in the amount of R$450,000, maturing on December 10, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On March 28, 2025, Proncor conducted the tenth private issue of nonconvertible, single-series, registered debentures in the amount of R$5,000, maturing on March 28, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On May 13, 2025, Proncor conducted the eleventh private issue of nonconvertible, single-series, registered debentures in the amount of R$22,690, maturing on May 13, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value were paid on the maturity date, plus yield. There are no guarantees for the debentures.
On July 24, 2025, Proncor conducted the twelfth private issue of nonconvertible, single-series, registered debentures in the amount of R$366,600, maturing on July 24, 2026; however, this term was extended to July 26, 2027. As of September 30, 2026, R$293,531 had been subscribed. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or.
Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On April 17, 2025, Acreditar conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R$181,000, initially maturing on April 17, 2026; however, this term was extended to April 20, 2027. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On April 17, 2025, Onco Dor Oncologia conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R$235,000, maturing on April 20, 2028. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
On April 18, 2025, Onco Dor BA Oncologia Ltda. (Cehon) carried out a private placement of book-entry nonconvertible commercial papers, without security interest or collateral security system, in a single series, of second issue, in the amount of R$75,800, maturing on April 20, 2027. The commercial papers may be fully or partially subscribed until the maturity date by Rede D'Or. Commercial notes not subscribed after this period will be automatically canceled. The commercial papers earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
On August 10, 2025, Oncologia Rede D'Or S.A. conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R$370,000, maturing on August 10, 2030. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100%
of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest is paid semiannually, and the nominal value will be paid on the maturity date. There are no guarantees for the debentures.
On August 10, 2025, São Rafael conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R$270,000, maturing on August 10, 2030. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.75% p.a. Interest is paid semiannually, and the nominal value will be paid on the maturity date. There are no guarantees for the debentures.
On November 24, 2025, SulAmérica Companhia de Seguro Saúde conducted the second private issue of nonconvertible, single-series, registered debentures amounting to R$1,000,000, maturing on November 18, 2033. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.10% p.a. Interest is paid semiannually, and the nominal value will be paid on the maturity date. There are no guarantees for the debentures.
On March 16, 2026, Mederi Distribuição e Importação de Produtos para a Saúde S.A. conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R$208,500, maturing on March 20, 2027. Until October 23, 2026, the Company had made early redemptions totaling R$54,395. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.90% p.a.; however, from October 26, 2026, the additional interest rate was increased to 4.00% p.a. Interest is paid semiannually, and the nominal value will be paid on the maturity date. There are no guarantees for the debentures.
Key management personnel compensation
The Company considers "Key management personnel" only the members of its Statutory Board and Board of Directors. At September 30, 2026 and 2025, key management personnel compensation is summarized as follows:
09/30/2026
09/30/2025
Salaries and bonuses
158,512
99,329
Benefits
372
291
Share-based payment
24,489
16,689
183,373
116,309
- Investments
Breakdown of and changes in investments - Individual
Equity
Capital increase/redu
ction/advance for future
capital
Company 12/31/2025
accounting Dividends
increase Transfer Other 09/30/2026
Medise Medicina Diagnóstico e Serviços S.A.
141,626
33,955
(48,812)
-
-
(2,263)
124,506
Hospital Esperança S.A.
4,968,562
223,984
(118,064)
140,808
-
-
5,215,290
PMJ Empreendimentos Imobiliários S.A. (a)
925,303
8,277
(24,471)
(27,352)
(269,572)
-
612,185
Norte D'Or Participações S.A. (including goodwill)
132,474
13,422
-
266
-
-
146,162
Onco D'Or Oncologia S.A.
297,402
166,583
-
-
-
(6,550)
457,435
Jenner S.A. (including goodwill)
68,836
69,329
-
-
-
(8,168)
129,997
JMJB Diagnósticos e Serviços Hospitalares
43,731
(5,181)
-
-
-
-
38,550
Hospital Fluminense S.A. (including goodwill)
348,315
65,116
(59,239)
(72,020)
-
-
282,172
Cardial Serviços Médicos (including goodwill)
177,515
57,937
(42,000)
-
-
1,310
194,762
TJK Empreendimentos Hospitalares
17,953
1,541
(2,491)
-
-
-
17,003
Santa Luzia II Empreendimentos Imobiliários Ltda.
60,114
(733)
-
(13,122)
-
-
46,259
Clínica São Vicente (a)/(b)
4,208,667
222,465
(156,083)
49,698
(108,386)
750,675
4,967,036
Rede D'or São Luiz Serviços Médicos S.A.
262,279
(44,938)
-
87,732
(5,612)
-
299,461
Laboratórios Richet
379,059
(28,227)
-
71,830
-
9,514
432,176
Qualicorp Consultoria e Corretora de Seguros S.A.
485,090
848
-
-
-
(242)
485,696
Clínica Médica São Remo
66,817
(4,912)
-
13,243
-
-
75,148
Hospital Santa Cruz
445,481
23,298
(6,337)
1,375
-
-
461,067
Advance Plano de Saúde S.A.
31,323
2,581
-
-
-
-
33,904
PrismaQuali Gestão Ativa de Participações S.A.
1,607,280
3,076
-
(4,657)
-
(1,322)
1,604,377
RDSLGF Greenfields Ltda.
915,759
39,961
(460)
5,675
147,888
18,006
1,126,829
RDSL OH Operações Hospitalares Ltda.
286,305
100,189
(5,040)
104,923
63,797
2,916
553,090
Traditio Companhia de Seguros
5,862,361
965,985
(203,152)
-
-
44,020
6,669,214
Cia Saúde - SulAmérica
5,245,987
1,170,018
(276,000)
-
-
55,067
6,195,072
SAEPAR Serviços e Participações
2,547,373
412,376
(76,900)
-
-
16,138
2,898,987
Other
1,942,636
10,997
(100,943)
137,587
(38,560)
8,510
1,960,227
31,468,248 3,507,947 (1,119,992) 493,236 (210,445) 887,611 35,026,605
On January 30, 2026, the Company completed the contribution of the assets and liabilities of Hospital Glória D'Or and SPE IH Glória D'Or to Atlântica D'Or.
On June 17, 2026, Clínica São Vicente, through its wholly-owned subsidiary Clínica São Lucas, acquired all shares in Biocor held by noncontrolling shareholders, representing 49% of the total shares, for R$129,200. The Company recognized a put/call option in financial liabilities amounting to R$495,211 at the exercise date. Accordingly, the liability was fully derecognized, resulting in an effect of R$366,011 arising from a capital transaction, recognized against equity attributable to noncontrolling shareholders. In addition, the amount recognized as noncontrolling interests in the consolidated financial statements, measured at fair value upon acquisition of control, was also added to the investment held by the parent company, with a corresponding entry to capital reserve, totaling R$750,675, with a corresponding entry recognized directly in equity, with no impact on profit or los s for the period (and no change in consolidated goodwill).
Capital
increase/advanc
Company 12/31/2025
Equity accounting
e for future
capital increase 09/30/2026
Onco Star
(596,939)
(96,314)
-
(693,253)
Centro Hospitalar São Marcos S.A.
(5,895)
(97)
139
(5,853)
Hospital São Marcos (including goodwill)
(69,889)
(227)
-
(70,116)
Rede D'Or Finance
(166,598) 5,785 - (160,813)
(839,321) (90,853) 139 (930,035)
Equity accounting
3,417,094
Company 12/31/2024
Equity
accounting Dividends
Capital
increase/reduction/ advance for future capital increase
Trans fers to assets held
for sale Trans fers Write-offs Other 09/30/2025
Medise Medicina Diagnóstico e Serviços S.A.
139,584
22,014
-
(29,146)
-
-
-
673
133,125
Hospital Esperança S.A.
5,175,670
258,626
(458,110)
(46,503)
-
(1,000)
-
-
4,928,683
PMJ Empreendimentos Imobiliários S.A.
889,825
15,738
(15,265)
26,397
-
(14,398)
-
-
902,297
Norte D'Or Participações S.A. (including goodwill)
133,602
(3,215)
-
510
-
-
-
-
130,897
Onco D'Or Oncologia S.A.
1,096,859
182,525
(895,593)
-
-
-
-
23,554
407,345
Jenner S.A. (including goodwill)
369,301
82,601
(346,276)
-
-
-
-
-
105,626
JMJB Diagnósticos e Serviços Hospitalares
44,811
(2,254)
-
-
-
-
-
-
42,557
Rodin Empreendimentos e Participações S.A.
447,492
(12,527)
-
30,553
-
-
(465,518)
-
-
Quinta Empreendimentos Imobiliários Ltda.
84,724
12,601
(16,482)
-
-
(22,918)
(57,925)
-
-
Hospital Fluminense S.A. (including goodwill)
317,729
32,548
(29,289)
3,525
-
-
-
-
324,513
Cardial Serviços Médicos (including goodwill)
137,980
49,692
(25,620)
-
-
-
-
-
162,052
TJK Empreendimentos Hospitalares
17,513
1,829
(1,950)
-
-
-
-
-
17,392
Villa Lobos Empreendimentos Imobiliários Ltda.
173,630
15,426
(1,770)
-
-
(34,322)
(152,964)
-
-
Santa Luzia II Empreendimentos Imobiliários Ltda.
61,572
(1,340)
-
-
-
-
-
-
60,232
Campinas Empreendimentos Imobiliários Ltda.
364,359
4,066
-
-
-
(363,197)
-
(5,228)
-
Sator Empreendimentos e Participações Ltda.
4,089,079
186,724
(78,181)
(275,883)
-
-
-
-
3,921,739
Rede D'or São Luiz Serviços Médicos S.A.
415,271
(11,792)
(76,673)
(85,141)
-
-
-
-
241,665
Olimpia Projeto Rua do Rocio 86 SPE S.A.
623,100
22,224
(3,504)
(37,421)
-
(31,037)
-
-
573,362
Laboratórios Richet
361,915
(8,839)
-
16,840
-
-
-
-
369,916
Santa Luzia III
306,751
16,728
-
5,513
-
(15,183)
(313,809)
-
-
Qualicorp Consultoria e Corretora de Seguros S.A.
484,640
(132)
(94)
-
-
-
-
(2)
484,412
Clínica Médica São Remo
58,453
(6,759)
-
11,269
-
-
-
-
62,963
Hospital Santa Cruz
433,842
20,495
(49,347)
17,082
-
-
-
-
422,072
Advance Plano de Saúde S.A.
40,419
(6,156)
-
-
-
-
-
-
34,263
Prisma Capital
1,604,880
(97)
-
-
-
-
-
-
1,604,783
RDSLGF Greenfields Ltda.
540,958
17,907
-
(13,652)
-
363,197
-
-
908,410
RDSL OH Operações Hospitalares Ltda.
114,943
72,652
-
128,451
-
-
-
-
316,046
Traditio Companhia de Seguros
5,002,876
867,903
-
136,641
-
-
-
(49,693)
5,957,727
Cia Saúde - SulAmérica
4,183,579
1,059,422
(211,439)
203,101
-
-
-
(51,849)
5,182,814
SAEPAR Serviços e Participações
2,183,881
373,931
-
62,715
-
-
-
(39,480)
2,581,047
Other
1,779,914
106,837
(86,781)
427,967
(225,005)
118,858
(235,481)
33,990
1,920,299
31,679,152
3,369,378
(2,296,374)
582,818
(225,005)
-
(1,225,697)
(88,035)
31,796,237
Company 12/31/2024
Equity accounting
Capital
increase/reduction/ advance for future
capital increase Other 09/30/2025
Onco Star
(454,758)
(99,986)
-
(5,966)
(560,710)
Centro Hospitalar São Marcos S.A.
(8,911)
51
15
-
(8,845)
Hospital São Marcos (including goodwill)
(97,039)
(28,381)
(4,904)
(4,743)
(135,067)
Rede D'Or Finance
(158,713) (2,599) - - (161,312)
(719,421) (130,915) (4,889) 10,709) (865,934)
Equity accounting
3,238,463
Breakdown of and changes in investments - Consolidated
Capital
increase/adva nce for future
Company
12/31/2025
Equity accounting
Dividends
capital increase
Other
09/30/2026
JMJB Diagnósticos e Serviços Hospitalares S.A.
43,731
(5,181)
-
-
-
38,550
Instituto de Radioterapia do Vale do Paraíba Ltda.
17,194
552
-
-
(206)
17,540
Qualicorp Consultoria e Corretora de Seguros S.A. (a)
2,089,212
3,652
-
-
(1,041)
2,091,823
Eldorado do Sul Participações Ltda.
10,707
5,777
(1,955)
-
(681)
13,848
Other
277,020
22,999
(12,062)
32,054
649
320,660
2,437,864
27,799
(14,017)
32,054
(1,279)
2,482,421
Equity
Acquisition of
Company 12/31/2024
accounting
control
Dividends
Other
Transfer
09/30/2025
JMJB Diagnósticos e Serviços Hospitalares S.A.
44,811
(2,254)
-
-
-
-
42,557
Instituto de Radioterapia do Vale do Paraíba Ltda.
16,686
661
-
-
(250)
-
17,097
Qualicorp Consultoria e Corretora de Seguros S.A. (a)
2,087,272
(568)
-
(404)
(9)
-
2,086,291
Eldorado do Sul Participações Ltda.
35,791
6,883
-
(28,853)
(47)
-
13,774
Other
298,996
24,077
1,666
(15,814)
-
(17,471)
291,454
2,483,556
28,799
1,666
(45,071)
(306)
(17,471)
2,451,173
Based on the shareholders' agreement entered into in November 2019, considering the nominations to the Executive Board and Board of Directors that the Company is entitled to, it was concluded that Rede D'Or has significant influence over Qualicorp; therefore, it records the investment using the equity method. The Company recognized the equity accounting through June 30, 2026, in accordance with IAS 28 (CPC 18) - Investments in Associates and Joint Ventures.
Summary of information on main subsidiaries
09/30/2026 09/30/2025
Operating
Profit or
Profit or
% Total
% Voting
capital
Assets
Liabilities
Equity
income
(expenses)
los s for the
period
los s for the
period
Direct and indirect subsidiaries
Medise Medicina Diagnóstico e Serviços S.A. ("Medise")
100.00
100.00
382,198
258,600
123,598
54,548
37,803
24,509
Hospital Esperança S.A. ("Esperança")
100.00
100.00
11,864,991
5,305,729
6,559,262
487,895
224,208
230,504
PMJ Empreendimentos Imobiliários S.A.
100.00
100.00
870,561
245,052
625,509
9,781
8,285
15,753
Norte D'Or Participações S.A.
100.00
100.00
117,755
5
117,750
13,254
13,435
(3,218)
Onco D'Or Oncologia S.A.
98.87
98.87
916,105
446,374
469,731
200,473
173,091
187,513
Jenner S.A.
91.24
91.24
170,741
24
170,717
138,535
138,657
150,730
JMJB Diagnósticos e Serviços Hospitalares S.A.
50.00
50.00
87,507
9,787
77,720
(10,362)
(5,181)
(2,254)
Hospital Fluminense S.A.
100.00
100.00
550,860
281,919
268,941
97,225
65,181
32,581
Cardial Serviços Médicos Ltda.
89.44
89.44
261,767
97,549
164,218
94,224
57,937
49,692
TJK Empreendimentos Imobiliários Ltda.
100.00
100.00
17,232
218
17,014
1,653
1,541
1,829
Santa Luzia II Emp. Imobiliários Ltda.
100.00
100.00
47,540
1,232
46,308
(1,571)
(733)
(1,340)
Clínica São Vicente
100.00
100.00
7,849,357
2,542,044
5,307,313
297,758
222,465
172,232
Rede D'Or Finance
100.00
100.00
12,191,804
12,352,617
(160,813)
(775)
5,785
(2,599)
Rede D'Or São Luiz Serviços Médicos S.A.
100.00
100.00
489,080
189,343
299,737
(70,627)
(44,942)
(11,793)
Laboratórios Richet
100.00
100.00
635,818
150,241
485,577
(23,611)
(28,255)
(8,847)
Onco Star SP Oncologia Ltda.
84.00
84.00
1,617,242
2,443,278
(826,036)
19,254
(96,314)
(99,986)
Centro Hospitalar São Marcos S.A
100.00
100.00
20
540
(520)
(97)
(97)
51
Hospital São Marcos
100.00
100.00
324,934
406,098
(81,164)
2,184
(227)
(28,410)
Clínica Médica São Remo
100.00
100.00
95,314
22,208
73,106
(3,825)
(4,912)
(6,760)
Hospital Santa Cruz
100.00
100.00
1,062,535
298,034
764,501
57,511
35,306
31,058
Advance Plano de Saúde S.A.
100.00
100.00
47,210
12,688
34,522
(49)
2,581
(6,157)
PrismaQuali Gestão Ativa de Participações S.A.
100.00
100.00
1,607,345
-
1,607,345
2,804
3,079
(97)
RDSLGF Greenfields Ltda.
100.00
100.00
1,129,432
23
1,129,409
39,815
39,961
17,907
RDSL OH Operações Hospitalares Ltda.
100.00
100.00
553,128
35
553,093
99,969
100,189
72,652
Traditio Companhia de Seguros
100.00
100.00
9,691,491
237,091
9,454,400
1,324,662
1,369,415
1,214,226
Cia Saúde - SulAmérica
100.00
100.00
32,954,559
19,489,279
13,465,280
3,312,097
2,543,517
2,261,009
SAEPAR Serviços e participações
100.00
100.00
3,014,424
115,437
2,898,987
417,925
412,376
373,931
Summary of the associates' and joint ventures' information
09/30/2026 09/30/2025
Profit or
% Total
ompanies recognized under the equity method in the consolidated financial statements
JMJB Diagnósticos e Serviços Hospitalares S.A.
50.00
50.00
87,504
9,786
77,718
(10,362)
(5,181)
(2,254)
Instituto de Radioterapia do Vale do Paraíba Ltda.
50.00
50.00
13,352
1,088
12,264
1,463
552
14.571
Eldorado do Sul Participações Ltda.
33.33
33.33
21,340
5,867
15,473
17,332
5,777
6,883
Qualicorp Consultoria e Corretora de Seguros S.A. (a)
25.85
25.85
3,431,058
2,077,419
1,353,639
(a)
(a)
(b)
C
% Voting
capital Assets Liabilities
.
Equity
Operating
income (expenses)
loss
for the period
Profit or loss for the period
The Company recognized the equity accounting until June 30, 2026.
The Company recognized the equity accounting until June 30, 2025.
Impairment
The recoverable amount of a CGU is determined based on the calculation of value in use. These calculations use cash flow projections based on financial budgets approved by management covering a five- to seven-year period. Assumptions are described in Note 10.
There is no indication of impairment of investments to date.
- Property and equipment
Balance breakdown
Individual
09/30/2026 12/31/2025
Description
Depreciation
rate Cost
Accumulated depreciation
Net
value Cost
Accumulated depreciation
Net value
Hospital machinery and equipment
12% to 20%
2,122,645
(1,610,403)
512,242
2,079,259
(1,566,315)
512,944
Surgical instruments
20%
150,704
(106,284)
44,420
160,996
(103,456)
57,540
Machinery and equipment
7% to 10%
1,208,597
(801,345)
407,252
1,149,655
(741,717)
407,938
Buildings
2.5% to 4%
893,776
(373,466)
520,310
968,848
(346,391)
622,457
Improvements in own buildings
4%
512,390
(223,567)
288,823
510,977
(209,161)
301,816
Leasehold improvements
3% to 4%
4,595,877
(1,046,903)
3,548,974
3,991,708
(915,466)
3,076,242
Furniture and fixtures
10%
317,117
(261,166)
55,951
307,366
(245,411)
61,955
Vehicles
20%
6,364
(5,182)
1,182
5,907
(4,965)
942
Facilities
10%
226,853
(132,428)
94,425
217,166
(119,897)
97,269
Land
-
147,698
-
147,698
147,698
-
147,698
Construction in progress
-
1,061,516
-
1,061,516
921,005
-
921,005
Other
5% to 10%
15,183
(8,128)
7,055
15,295
(7,862)
7,433
11,258,720
(4,568,872)
6,689,848
10,475,880
(4,260,641)
6,215,239
Consolidated
09/30/2026
12/31/2025
Depreciation
Accumulated
Net
Accumulated
Net
Description
rate
Cost
depreciation
value
Cost
depreciation
value
Hospital machinery and equipment
12% to 20%
4,499,955
(3,069,802)
1,430,153
4,255,122
(2,807,142)
1,447,980
Surgical instruments
20%
409,498
(255,274)
154,224
384,211
(228,297)
155,914
Machinery and equipment
7% to 10%
2,002,528
(1,281,220)
721,308
1,876,669
(1,181,256)
695,413
Buildings
2.5% to 4%
5,952,866
(1,265,441)
4,687,425
5,887,248
(1,084,168)
4,803,080
Improvements in own buildings
4%
1,226,423
(345,211)
881,212
1,056,420
(310,001)
746,419
Leasehold improvements
3% to 4%
7,609,233
(1,571,518)
6,037,715
6,530,521
(1,356,330)
5,174,191
Furniture and fixtures
10%
617,869
(445,828)
172,041
581,154
(412,023)
169,131
Vehicles
20%
30,860
(27,987)
2,873
30,104
(27,303)
2,801
Facilities
10%
529,162
(264,089)
265,073
509,626
(237,609)
272,017
Land
-
1,315,565
-
1,315,565
1,304,085
-
1,304,085
Construction in progress
-
2,482,611
-
2,482,611
1,967,776
-
1,967,776
Other
5% to 10%
63,812
(12,955)
50,857
62,922
(11,799)
51,123
26,740,382
(8,539,325)
18,201,057
24,445,858
(7,655,928)
16,789,930
Changes - Individual
12/31/2025
Additions
Transfers (a)
09/30/2026
Cost
Hospital machinery and equipment
2,079,259
102,102
(58,716)
2,122,645
Surgical instruments
160,996
11,559
(21,851)
150,704
Machinery and equipment
1,149,655
69,912
(10,970)
1,208,597
Buildings
968,848
46
(75,118)
893,776
Improvements in own buildings
510,977
811
602
512,390
Leasehold improvements
3,991,708
326,473
277,696
4,595,877
Furniture and fixtures
307,366
14,646
(4,895)
317,117
Vehicles
5,907
457
-
6,364
Facilities
217,166
11,389
(1,702)
226,853
Land
147,698
-
-
147,698
Construction in progress
921,005
434,806
(294,295)
1,061,516
Other
15,295
50
(162)
15,183
10,475,880
972,251
(189,411)
11,258,720
Depreciation
Hospital machinery and equipment
(1,566,315)
(80,862)
36,774
(1,610,403)
Surgical instruments
(103,456)
(10,809)
7,981
(106,284)
Machinery and equipment
(741,717)
(65,859)
6,231
(801,345)
Buildings
(346,391)
(28,327)
1,252
(373,466)
Improvements in own buildings
(209,161)
(14,406)
-
(223,567)
Leasehold improvements
(915,466)
(133,858)
2,421
(1,046,903)
Furniture and fixtures
(245,411)
(17,317)
1,562
(261,166)
Vehicles
(4,965)
(217)
-
(5,182)
Facilities
(119,897)
(12,805)
274
(132,428)
Other
(7,862)
(298)
32
(8,128)
(4,260,641)
(364,758)
56,527
(4,568,872)
Property and equipment, net
6,215,239
607,493
(132,884)
6,689,848
The effect of R$132,884 relates to the transfer of assets of Hospital São Luiz Maternidade Star from the parent company to "Atlântica D'Or".
12/31/2024
Additions
Transfers (a)
09/30/2025
Cost
Hospital machinery and equipment
1,843,976
227,112
(57,922)
2,013,166
Surgical instruments
146,112
9,569
(1,183)
154,498
Machinery and equipment
1,057,171
52,184
(6,067)
1,103,288
Buildings
892,674
1,037
-
893,711
Improvements in own buildings
488,456
12,764
7,972
509,192
Leasehold improvements
3,382,389
220,791
76,479
3,679,659
Furniture and fixtures
279,474
17,814
(807)
296,481
Vehicles
5,907
-
-
5,907
Facilities
170,881
33,856
(64)
204,673
Land
147,698
-
-
147,698
Construction in progress
1,097,248
122,807
(95,262)
1,124,793
Other
14,800
395
(5)
15,190
9,526,786
698,329
(76,859)
10,148,256
Depreciation
Hospital machinery and equipment
(1,473,756)
(121,996)
17,894
(1,577,858)
Surgical instruments
(86,720)
(12,645)
386
(98,979)
Machinery and equipment
(650,215)
(84,505)
653
(734,067)
Buildings
(308,517)
(27,841)
-
(336,358)
Improvements in own buildings
(190,572)
(13,790)
-
(204,362)
Leasehold improvements
(769,766)
(105,827)
30
(875,563)
Furniture and fixtures
(218,689)
(19,914)
112
(238,491)
Vehicles
(4,812)
(98)
-
(4,910)
Facilities
(103,611)
(11,708)
6
(115,313)
Other
(7,348)
(374)
-
(7,722)
(3,814,006)
(398,698)
19,081
(4,193,623)
Property and equipment, net
5,712,780
299,631
(57,778)
5,954,633
The effect of R$57,778 relates to the transfer of assets of Hospital São Luiz Campinas from the parent company to "Atlântica D'Or".
Changes - Consolidated
12/31/2025
Additions
Transfers
09/30/2026
Cost
Hospital machinery and equipment
4,255,122
244,833
-
4,499,955
Surgical instruments
384,211
25,287
-
409,498
Machinery and equipment
1,876,669
125,859
-
2,002,528
Buildings
5,887,248
65,618
-
5,952,866
Improvements in own buildings
1,056,420
98,490
71,513
1,226,423
Leasehold improvements
6,530,521
521,305
557,407
7,609,233
Furniture and fixtures
581,154
36,715
-
617,869
Vehicles
30,104
756
-
30,860
Facilities
509,626
19,536
-
529,162
Land
1,304,085
11,480
-
1,315,565
Construction in progress
1,967,776
1,143,755
(628,920)
2,482,611
Other
62,922
890
-
63,812
24,445,858
2,294,524
-
26,740,382
Depreciation
Hospital machinery and equipment
(2,807,142)
(262,660)
-
(3,069,802)
Surgical instruments
(228,297)
(26,977)
-
(255,274)
Machinery and equipment
(1,181,256)
(99,964)
-
(1,281,220)
Buildings
(1,084,168)
(181,273)
-
(1,265,441)
Improvements in own buildings
(310,001)
(35,210)
-
(345,211)
Leasehold improvements
(1,356,330)
(215,188)
-
(1,571,518)
Furniture and fixtures
(412,023)
(33,805)
-
(445,828)
Vehicles
(27,303)
(684)
-
(27,987)
Facilities
(237,609)
(26,480)
-
(264,089)
Other
(11,799)
(1,156)
-
(12,955)
(7,655,928)
(883,397)
-
(8,539,325)
Property and equipment, net
16,789,930
1,411,127
-
18,201,057
12/31/2024
Additions
Transfers
Transfers to as sets held for sale
09/30/2025
Cost
Hospital machinery and equipment
3,710,404
445,445
-
(29,131)
4,126,718
Surgical instruments
341,803
29,695
-
-
371,498
Machinery and equipment
1,631,824
195,104
-
(103,057)
1,723,871
Buildings
4,773,617
792,056
294,124
-
5,859,797
Improvements in own buildings
854,783
70,623
83,732
-
1,009,138
Leasehold improvements
5,251,827
378,954
402,808
(44,717)
5,988,872
Furniture and fixtures
548,445
29,873
-
(10,470)
567,848
Vehicles
30,666
-
-
(1,387)
29,279
Facilities
455,622
70,778
-
(60,595)
465,805
Land
1,270,421
20,899
-
(3,342)
1,287,978
Construction in progress
2,590,389
397,334
(780,664)
(4,611)
2,202,448
Other
61,736
1,043
-
(3,904)
58,875
21,521,537
2,431,804
-
(261,214)
23,692,127
Depreciation
Hospital machinery and equipment
(2,470,553)
(284,838)
-
13,524
(2,741,867)
Surgical instruments
(188,909)
(28,448)
-
-
(217,357)
Machinery and equipment
(1,018,232)
(135,466)
-
47,924
(1,105,774)
Buildings
(862,555)
(159,265)
-
-
(1,021,820)
Improvements in own buildings
(265,916)
(33,132)
-
-
(299,048)
Leasehold improvements
(1,129,152)
(165,889)
-
23,751
(1,271,290)
Furniture and fixtures
(366,340)
(34,274)
-
6,608
(394,006)
Vehicles
(26,822)
(288)
-
1,378
(25,732)
Facilities
(204,747)
(25,997)
-
13,518
(217,226)
Other
(9,853)
(1,655)
-
2,176
(9,332)
(6,543,079)
(869,252)
-
108,879
(7,303,452)
Property and equipment, net
14,978,458
1,562,552
-
(152,335)
16,388,675
Significant changes for the periods ended September 30, 2026 and 2025 were as follows: 2026
Investments in the expansion works of hospital facilities such as Hospital Itaim and Hospital Caxias D'Or, as well as the new towers of Hospitals Santa Luzia Star, UDI, and São Lucas.
Capital expenditures on improvements aimed at the expansion and growth of hospitals, primarily São Lucas, Central Tatuapé, and Morumbi.
Purchases of medical and hospital machinery and equipment for Hospitals DF Star, Vila Nova Star, Caxias D'Or, Oeste D'Or and Anália, as well as for the Atlântica D'Or Complex.
Investments in construction works of Hospitals Ribeirão Preto, Sorocaba and Taubaté.
2025
Investments in the expansion works of hospital facilities such as Hospital Assunção, São Vicente, Onco Star and the new tower of UDI Hospital.
Expenses with improvements for the growth and expansion of hospitals and clinics, primarily Hospitals São Lucas, Assunção, Morumbi, and UDI.
Purchases of hospital machinery and equipment for the Hospitals new Barra D'Or, Anália, Hospital Assunção, Onco Star, Aliança, and São Vicente.
Investments in construction works of Hospitals Taubaté and Ribeirão Preto.
Capitalized borrowing costs
The Company capitalizes borrowing costs attributable to qualifying assets. At September 30, 2026, R$99,092 (R$128,827 at September 30, 2025) in interest on loans and financing were capitalized in Property and equipment.
Impairment testing of property and equipment
Management has assessed the existence of events or changes in economic, operational or technological circumstances and has not identified any evidence that could indicate deterioration or impairment of property and equipment.
- Intangible ass ets
Annual Individual Consolidated
amortization rate | 09/30/2026 | 12/31/2025 | 09/30/2026 | 12/31/2025 | |
Finite useful life Software | 20% | 300,679 | 324,987 | 772,753 | 802,283 |
Customer portfolio - SASA | 11% to 20% | 73,189 | 100,077 | 73,189 | 100,077 |
Exclusive agreements | 20% | 11,579 | 14,727 | 92,712 | 102,950 |
Other | - | - | 3,155 | 5,920 |
Indefinite useful life Goodwill
Acquisition of Copa D'Or | 80,058 | 80,058 | 80,058 | 80,058 |
Acquisition of HMSL | 668,339 | 668,339 | 668,339 | 668,339 |
Acquisition of Hospital Brasil | 121,398 | 121,398 | 121,398 | 121,398 |
Acquisition of Hospital Prontolinda | 30,595 | 30,595 | 30,595 | 30,595 |
Acquisition of Vivalle | 38,692 | 38,692 | 38,692 | 38,692 |
Acquisition of São Marcos | - | - | 10,807 | 10,807 |
Acquisition of Santa Luzia | 199,333 | 199,333 | 199,333 | 199,333 |
Acquisition of Sinisgalli | 156,646 | 156,646 | 156,646 | 156,646 |
Acquisition of Hospital Esperança | - | - | 108,408 | 108,408 |
Acquisition of Norte D'Or | - | - | 28,450 | 28,450 |
Acquisition of IFOR | 85,724 | 85,724 | 85,724 | 85,724 |
Acquisition of Sino Brasileiro | 241,947 | 241,947 | 241,947 | 241,947 |
Acquisition of Villa-Lobos | 136,074 | 136,074 | 136,074 | 136,074 |
Acquisition of Bartira | 105,584 | 105,584 | 105,584 | 105,584 |
Acquisition of Onco ABC/Cardeal/JLD | - | - | 55,414 | 55,414 |
Acquisition of Oncoholding | - | - | 159,445 | 159,445 |
Acquisition of Hospital Fluminense | - | - | 10,658 | 10,658 |
Acquisition of Hospital Santa Helena | 125,802 | 125,802 | 125,802 | 125,802 |
Acquisition of Acreditar | - | - | 155,720 | 155,720 |
Acquisition of Memorial São Jose | 112,528 | 112,528 | 112,528 | 112,528 |
Acquisition of Alpha-Med | - | - | 43,815 | 43,815 |
Acquisition of CEHON | - | - | 68,757 | 68,757 |
Acquisition of Maximagem | 46,742 | 46,742 | 46,742 | 46,742 |
Acquisition of Ribeirão Pires | 129,739 | 129,739 | 129,739 | 129,739 |
Acquisition of NEOH | - | - | 33,422 | 33,422 |
Acquisition of Salus | - | - | 8,956 | 8,956 |
Acquisition of Prontimagem | - | - | 6,220 | 6,220 |
Acquisition of Sator | - | - | 163,089 | 163,089 |
Acquisition of Hospital São Rafael | - | - | 509,363 | 509,363 |
Acquisition of Laboratório Richet | - | - | 184,232 | 184,232 |
Acquisition of UDI | - | - | 335,883 | 335,883 |
Acquisition of Samer | - | - | 70,939 | 70,939 |
Acquisition of Hospital Rio Mar | - | - | 94,833 | 94,833 |
Acquisition of Hospital São Lucas | - | - | 223,079 | 223,079 |
Acquisition of Hospital Aviccena | 60,476 | 60,476 | 60,476 | 60,476 |
Acquisition of Perinatal | 655,580 | 655,580 | 655,580 | 655,580 |
Acquisition of Hospital Santa Cruz | - | - | 299,583 | 299,583 |
Acquisition of Aliança | - | - | 925,555 | 925,555 |
Acquisition of Salute | - | - | 15,475 | 15,475 |
Acquisition of São Carlos | - | - | 160,139 | 160,139 |
Acquisition of Clínica São Lucas | - | - | 45,673 | 45,673 |
Acquisition of Clivalle | - | - | 40,786 | 40,786 |
Acquisition of HCP/Cárdio Pulmonar | - | - | 146,894 | 146,894 |
Acquisition of Guaianases | - | - | 115,751 | 115,751 |
Acquisition of Antônio Afonso | - | - | 16,782 | 16,782 |
Acquisition of Balbino | - | - | 77,500 | 77,500 |
Acquisition of América | - | - | 456,511 | 456,511 |
Acquisition of Serra Mayor | - | - | 68,981 | 68,981 |
Acquisition of Biocor | - | - | 561,269 | 620,347 |
Acquisition of Proncor | - | - | 202,929 | 202,929 |
Acquisition of Santa Emilia | - | - | 121,991 | 121,991 |
Acquisition of Hospital Nossa Senhora das Neves | - | - | 326,634 | 326,634 |
Acquisition of HNSN Empreendimentos | - | - | 34,790 | 34,790 |
Acquisition of Orthoservice | - | - | 33,705 | 33,705 |
Acquisition of HNA Emp. E Participações | - | - | 12,401 | 12,401 |
Acquisition of Hospital Novo Atibaia | - | - | 173,020 | 173,020 |
Acquisition of Hospital Arthur Ramos | - | - | 272,686 | 272,686 |
Acquisition of Hospital Santa Isabel | - | - | 243,287 | 243,287 |
Acquisition of Hospital Aeroporto | - | - | 171,511 | 171,511 |
Acquisition of Paraná Clínicas | - | - | 284,701 | 284,701 |
Acquisition of Sompo Saúde | - | - | 199,384 | 199,384 |
Acquisition of Prodent | - | - | 106,681 | 106,681 |
Acquisition of SASA | 1,820,625 | 1,820,625 | 1,820,625 | 1,820,625 |
Other goodwill | 48,650 | 48,650 | 294,096 | 277,329 |
Trademark - SASA | 2,068,575 | 2,068,575 | 2,068,575 | 2,068,575 |
Trademarks and patents (a) 190,810 190,810 190,986 190,816
7,509,364 7,563,708 15,697,457 15,809,019
(a) This mainly refers to the Hospital São Luiz trademark registered upon its acquisition in 2010.
Software development costs and licenses
These refer mainly to expenditures incurred with the development of technological infrastructure, applications, improvements in the companies' website and in operations of Sul América S.A., development of own systems, and acquisition of software licenses used in operations.
Impairment
Goodwill is allocated to the Cash-Generating Units (CGU) identified by management, i.e. each hospital, as shown in the table above.
The recoverable amount of a CGU is determined based on the calculation of value in use. Value in use calculations use cash flow projections based on financial budgets approved by
management covering a five-year period.
Discount rates represent the current market assessment of the risks specific to each CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and is derived from its weighted average cost of capital (WACC). The WACC takes into consideration both debt and equity. The cost of equity is derived from the expected return on investment by the investors. The cost of debt is based on the interest-bearing financing the Company is obliged to service. Segment-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data.
There is no indication of impairment of intangible assets to date.
